Menopause can produce several problems at the same time, but they do not all respond to the same treatment. A woman may have severe night sweats without vaginal symptoms, persistent vaginal dryness after her hot flashes have largely disappeared, or sleep and mood problems that are partly related to repeated nighttime awakenings.

For this reason, menopause treatment usually begins by identifying which symptoms are actually causing difficulty and then selecting a medicine that reaches the tissues or biological pathway involved. Hormonal treatment remains an important option, but prescription care now also includes several non-hormonal medicines developed or used specifically to reduce menopausal symptoms.

Begin by Separating the Symptoms Into Treatment Tracks

Before discussing a particular drug, it helps to determine what the treatment is expected to accomplish. Menopause symptoms can overlap, but four groups commonly lead to different medication decisions:

• Hot flashes and night sweats usually require a systemic treatment that affects temperature regulation throughout the body.
• Vaginal dryness, burning, painful intercourse, and some urinary symptoms can often be treated directly in vaginal tissue without using a full systemic regimen.
• Sleep or mood problems may improve when hot flashes are controlled, although some women require treatment directed specifically at insomnia, depression, or anxiety.
• Irregular or heavy bleeding during perimenopause requires a different assessment because contraception, uterine conditions, and the pattern of menstrual bleeding can influence treatment.

This distinction prevents every symptom occurring in the 40s or 50s from being treated simply as “low estrogen.” Menopause generally occurs around age 51, but symptoms often begin during perimenopause while menstrual periods are still occurring and hormone production is fluctuating.

The American College of Obstetricians and Gynecologists describes hot flashes, sleep problems, vaginal changes, and menstrual irregularity among the problems that can develop during this transition.

The First Prescription Decision Is Often Local Treatment or Systemic Treatment

A useful distinction in menopause care is not simply “hormonal versus non-hormonal.” The first practical question may be whether medication needs to circulate throughout the body at all.

This is why a woman with isolated vaginal dryness may not need the same treatment as someone experiencing ten disruptive hot flashes every day. The Office on Women’s Health describes both systemic hormone treatment and local vaginal therapies as prescription options, with the choice depending on the symptoms being treated and the woman’s individual health profile.

When Hot Flashes Are the Main Problem, Hormone Therapy Is One Route

Systemic menopausal hormone therapy remains the most effective medication approach for vasomotor symptoms, which include hot flashes and night sweats. Estrogen can be delivered through an oral tablet, skin patch, gel, or spray. The route matters because oral and transdermal products do not have identical pharmacologic effects or risk profiles, so the prescription may change according to cardiovascular risk, history of blood clots, liver disease, migraine, other medications, and personal preference.

The presence or absence of the uterus is another major treatment decision. Estrogen stimulates the endometrium. A woman who still has her uterus therefore generally receives adequate progestogen protection with systemic estrogen to reduce the risk of endometrial hyperplasia and cancer. Someone who has undergone hysterectomy can usually receive estrogen without a progestogen. The ACOG hormone therapy guidance explains this distinction and the different systemic formulations used for menopausal symptoms.

Prescription hormone treatment can consequently take several forms instead of one standard “menopause pill”:

• oral estrogen alone after hysterectomy;
• transdermal estradiol delivered through a patch;
• estradiol gel or spray applied to the skin;
• estrogen combined with a progestogen;
• estrogen prescribed separately from oral micronized progesterone or another progestogen.

Choice of formulation is individualized. A patient should not assume that a medication used successfully by a friend or relative is appropriate for her own medical history.

If Hormones Are Not Wanted or Not Appropriate, Hot Flashes Still Have Prescription Options

Non-hormonal treatment has expanded considerably. It is no longer limited to trying an antidepressant because estrogen cannot be used. Several medication classes act on pathways involved in vasomotor symptoms, and newer medicines were developed specifically for menopausal hot flashes.

If you want to review the available options before deciding which prescription to discuss with your doctor, you can browse the Women’s Health section of Global Canadian Pharmacy, an online prescription service, where brand-name and generic versions can be compared and then discussed with your prescriber to determine which medicine, strength, and formulation should be ordered.

Prescription choices may include:

• SSRIs and SNRIs. Certain medicines in these antidepressant classes can reduce the frequency or severity of hot flashes even in women who are not being treated for depression. Low-dose paroxetine has an FDA-approved indication for moderate to severe vasomotor symptoms, while other agents are used based on clinical evidence and individual circumstances.
• Gabapentin. This neurologic medicine can reduce vasomotor symptoms and may be useful when night sweats and nighttime awakening are particularly troublesome.
• Fezolinetant. Sold as Veozah, this non-hormonal medicine blocks neurokinin-3 receptors involved in temperature regulation.
• Elinzanetant. Sold as Lynkuet, this newer neurokinin-targeting treatment was approved in the United States in 2025 for moderate to severe vasomotor symptoms due to menopause.

The 2023 Nonhormone Therapy Position Statement from The Menopause Society reviews evidence-supported non-hormonal approaches for women who cannot or prefer not to use hormone therapy.

Fezolinetant Requires More Than Simply Filling a Prescription

Fezolinetant illustrates why the monitoring requirements of a medicine can matter when selecting treatment. It acts on the brain’s thermoregulatory pathway without supplying estrogen, making it an option for moderate to severe vasomotor symptoms. However, postmarketing reports identified rare cases of serious liver injury.

The FDA subsequently added a boxed warning and specific liver-testing requirements. Current FDA safety guidance for Veozah calls for hepatic laboratory testing before treatment, monthly during the first three months, and again at months 6 and 9. Symptoms that can indicate liver injury, including jaundice, dark urine, unusual itching, persistent nausea, and upper abdominal pain, require prompt attention.

That monitoring burden may make another treatment more appropriate for some women even when fezolinetant would otherwise be a reasonable option. Medication selection therefore involves more than comparing how effectively different drugs reduce hot flashes.

A Newer Non-Hormonal Option Targets Two Neurokinin Receptors

Elinzanetant provides another example of how menopause pharmacotherapy has moved beyond estrogen and repurposed antidepressants. The medicine acts as an antagonist at neurokinin-1 and neurokinin-3 receptors involved in the neural pathways associated with thermoregulation.

The FDA approved Lynkuet on October 24, 2025, for moderate to severe vasomotor symptoms due to menopause. In the OASIS-1 and OASIS-2 trials, treatment reduced both the frequency and severity of moderate to severe vasomotor symptoms compared with placebo. The FDA Drug Trials Snapshot for Lynkuet describes the clinical studies and the population included in the approval program.

Having more than one non-hormonal pathway is clinically useful because intolerance, interactions, coexisting conditions, and previous treatment response can make one medicine a better fit than another.

Vaginal and Urinary Symptoms Follow a Different Treatment Path

Genitourinary syndrome of menopause can include vaginal dryness, burning, irritation, pain during intercourse, urinary urgency, discomfort with urination, and recurrent urinary problems. These symptoms often persist after hot flashes have improved and may gradually become more troublesome without treatment.

For women whose symptoms are limited mainly to vaginal and vulvar tissues, treatment can begin with vaginal moisturizers and lubricants. Persistent symptoms may lead to prescription therapy, including low-dose vaginal estrogen in the form of a cream, tablet, insert, or ring. Because these products are designed primarily for local treatment, systemic estrogen exposure is substantially lower than with conventional systemic hormone therapy.

Other prescription possibilities include vaginal prasterone for pain with intercourse and oral ospemifene, a selective estrogen receptor modulator used for specific vulvovaginal symptoms. A history of estrogen-dependent cancer changes this discussion. ACOG guidance for patients with previous estrogen-dependent breast cancer recommends starting with non-hormonal approaches and using shared decision-making when low-dose vaginal hormonal treatment is being considered.

Perimenopause Can Require a Different Prescription Than Postmenopause

A woman who is still having periods may need treatment for several issues simultaneously. Hot flashes can occur while ovulation remains possible, which means contraception may still be necessary. Heavy or unpredictable bleeding may also be part of the clinical picture.

Depending on age, smoking status, blood pressure, clotting risk, migraine history, and other factors, a clinician may consider low-dose hormonal contraception during perimenopause instead of a conventional postmenopausal hormone regimen. This can sometimes address contraception, irregular bleeding, and vasomotor symptoms with one treatment plan.

Bleeding should not automatically be attributed to menopause, however. Persistent heavy bleeding, bleeding after intercourse, substantial changes in menstrual pattern, or any bleeding after established menopause can require evaluation for structural uterine disease, endometrial abnormalities, or other causes before medication is adjusted.

Hormones Used for Symptoms Are Different From Hormones Used to Prevent Disease

Another important distinction concerns the purpose of treatment. Menopausal hormone therapy can be prescribed to relieve clinically significant hot flashes, night sweats, and other symptoms. That is different from giving estrogen to an otherwise asymptomatic postmenopausal woman solely in an attempt to prevent cardiovascular disease, dementia, or other chronic conditions.

The U.S. Preventive Services Task Force recommends against estrogen alone or combined estrogen-progestin therapy for the primary prevention of chronic medical conditions in asymptomatic postmenopausal people. The recommendation specifically does not apply to the use of hormone therapy for menopausal symptoms such as hot flashes or vaginal dryness.

What Should Be Reviewed After Treatment Starts?

A prescription is the beginning of treatment, not the end of the decision process. Follow-up should establish whether the medicine is controlling the symptom that prompted treatment and whether adverse effects or new health issues have appeared.

A practical medication review can include:

1. Measure the symptom that mattered initially. This may mean tracking the number of hot flashes, nighttime awakenings, episodes of painful intercourse, or another specific problem.
2. Review adverse effects. Breast tenderness, bleeding, gastrointestinal effects, sedation, sexual side effects, blood pressure changes, or other problems may influence the next decision.
3. Check required monitoring. Some medicines require laboratory follow-up or additional clinical surveillance.
4. Reconsider the dose and formulation. Persistent symptoms do not automatically mean that more medication is needed; the route, diagnosis, adherence, or treatment target may need to change.
5. Review newly prescribed drugs. Another medication can create an interaction or alter the risk-benefit balance of the menopause treatment.

Women should also report symptoms that do not fit the expected treatment course. The Office on Women’s Health menopause guidance provides additional information on the range of symptoms that can occur during the transition and the circumstances in which medical treatment may be considered.

Additional Information

1. Hormone Therapy for Menopause – https://medlineplus.gov/hormonetherapyformenopause.html
2. Menopause: Diagnosis and Treatment – https://www.mayoclinic.org/diseases-conditions/menopause/diagnosis-treatment/drc-20353401
3. What Is Menopause? – https://www.nia.nih.gov/health/menopause/what-menopause
4. Treatment for Menopause and Perimenopause – https://www.nhs.uk/conditions/menopause-and-perimenopause/treatment/
5. Menopause: Identification and Management – https://www.nice.org.uk/guidance/ng23/
6. Hormone Therapy for Menopause Symptoms – https://my.clevelandclinic.org/health/treatments/15245-hormone-therapy-for-menopause-symptoms
7. Introduction to Menopause – https://www.hopkinsmedicine.org/health/conditions-and-diseases/introduction-to-menopause

Disclaimer

This article is intended for general informational purposes and does not replace individualized medical advice, diagnosis, or treatment. Menopause symptoms, medication risks, and treatment goals can differ substantially from one person to another.